JP7427287B2 - 二重ｉｌ－２ｒおよびｉｌ－７ｒ結合化合物 - Google Patents

二重ｉｌ－２ｒおよびｉｌ－７ｒ結合化合物 Download PDF

Info

Publication number
JP7427287B2
JP7427287B2 JP2022525813A JP2022525813A JP7427287B2 JP 7427287 B2 JP7427287 B2 JP 7427287B2 JP 2022525813 A JP2022525813 A JP 2022525813A JP 2022525813 A JP2022525813 A JP 2022525813A JP 7427287 B2 JP7427287 B2 JP 7427287B2
Authority
JP
Japan
Prior art keywords
ligand
ligands
seq
rγc
formulas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022525813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553826A (ja
JP2022553826A5 (https=
JPWO2021092081A5 (https=
Inventor
ダウアー、ウィリアム、ジェイ．
ニーデルズ、マイケル、シー．
バレット、ローランド、ダブリュー．
バッカー、アリス、ブイ．
クウィルラ、スティーブン、イー．
Original Assignee
メディカイン、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディカイン、インコーポレイテッド filed Critical メディカイン、インコーポレイテッド
Publication of JP2022553826A publication Critical patent/JP2022553826A/ja
Publication of JP2022553826A5 publication Critical patent/JP2022553826A5/ja
Publication of JPWO2021092081A5 publication Critical patent/JPWO2021092081A5/ja
Priority to JP2024005177A priority Critical patent/JP2024056696A/ja
Application granted granted Critical
Publication of JP7427287B2 publication Critical patent/JP7427287B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022525813A 2019-11-05 2020-11-04 二重ｉｌ－２ｒおよびｉｌ－７ｒ結合化合物 Active JP7427287B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024005177A JP2024056696A (ja) 2019-11-05 2024-01-17 二重ｉｌ－２ｒおよびｉｌ－７ｒ結合化合物

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962930758P 2019-11-05 2019-11-05
US62/930,758 2019-11-05
US202062969432P 2020-02-03 2020-02-03
US62/969,432 2020-02-03
US202063041158P 2020-06-19 2020-06-19
US63/041,158 2020-06-19
US202063071946P 2020-08-28 2020-08-28
US63/071,946 2020-08-28
PCT/US2020/058969 WO2021092081A1 (en) 2019-11-05 2020-11-04 Dual il-2r and il-7r binding compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024005177A Division JP2024056696A (ja) 2019-11-05 2024-01-17 二重ｉｌ－２ｒおよびｉｌ－７ｒ結合化合物

Publications (4)

Publication Number Publication Date
JP2022553826A JP2022553826A (ja) 2022-12-26
JP2022553826A5 JP2022553826A5 (https=) 2023-04-19
JPWO2021092081A5 JPWO2021092081A5 (https=) 2023-04-19
JP7427287B2 true JP7427287B2 (ja) 2024-02-05

Family

ID=75686972

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525813A Active JP7427287B2 (ja) 2019-11-05 2020-11-04 二重ｉｌ－２ｒおよびｉｌ－７ｒ結合化合物
JP2024005177A Withdrawn JP2024056696A (ja) 2019-11-05 2024-01-17 二重ｉｌ－２ｒおよびｉｌ－７ｒ結合化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024005177A Withdrawn JP2024056696A (ja) 2019-11-05 2024-01-17 二重ｉｌ－２ｒおよびｉｌ－７ｒ結合化合物

Country Status (11)

Country Link
US (2) US11248030B2 (https=)
EP (1) EP4055036A4 (https=)
JP (2) JP7427287B2 (https=)
KR (1) KR20220110209A (https=)
AU (2) AU2020378282B2 (https=)
BR (1) BR112022008750A2 (https=)
CA (1) CA3160466A1 (https=)
IL (1) IL292803A (https=)
MX (1) MX2022005404A (https=)
TW (1) TW202132330A (https=)
WO (1) WO2021092081A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021201047B2 (en) * 2018-08-06 2022-02-17 Medikine, Inc. Il-2 receptor binding compounds
MX2021001493A (es) 2018-08-06 2021-07-15 Medikine Inc Compuestos de fijación al receptor de il-2.
KR20220110207A (ko) * 2019-11-05 2022-08-05 메디카인 인코포레이티드 IL-2RβγC 결합 화합물
MX2022005404A (es) * 2019-11-05 2022-09-09 Medikine Inc Compuestos de fijación a il-2r e il-7r dual.
IL295304A (en) * 2020-02-03 2022-10-01 Medikine Inc Il-7 receptor alpha gamma c binding compounds, compositions comprising same and uses thereof
KR20230097168A (ko) * 2020-11-04 2023-06-30 메디카인 인코포레이티드 IL-2Rβγc 결합 화합물 및 이의 용도
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US11999771B2 (en) * 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
WO2024054870A1 (en) * 2022-09-06 2024-03-14 Medikine, Inc. Use of il-7r-alpha-gamma agonist peptides in cell manufacturing
US20240101959A1 (en) * 2022-09-06 2024-03-28 Medikine, Inc. Use of il-2r-beta-gamma agonist peptides in cell manufacturing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136818A2 (en) 2016-02-05 2017-08-10 Washington University Compositions and methods for targeted cytokine delivery
JP2017528444A (ja) 2014-08-11 2017-09-28 デリニア， インコーポレイテッド 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635597A (en) * 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
PT1454138E (pt) * 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
DK1648931T3 (da) * 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
CA2551915C (en) 2003-12-30 2015-06-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Il-7 fusion proteins
WO2010099084A2 (en) 2009-02-27 2010-09-02 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from corn and methods of using those molecules
ES2866674T3 (es) 2010-11-12 2021-10-19 Nektar Therapeutics Conjugados de una fracción de IL-2 y un polímero
US9266937B2 (en) 2010-12-10 2016-02-23 University Of Central Florida Research Foundation, Inc. Compositions comprising IL-7 receptor ligands
HRP20200470T1 (hr) 2011-01-18 2020-10-02 Bioniz, Llc Pripravci za modulaciju aktivnosti gama-c-citokina
CN102775496B (zh) * 2011-05-13 2014-10-08 中国医学科学院基础医学研究所 靶向清除hiv/siv的复合药物
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
GB2538666A (en) 2014-07-21 2016-11-23 Delinia Inc Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
PT3328894T (pt) 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
JP2019518786A (ja) * 2016-05-06 2019-07-04 牧林 王 インターロイキンの組み合せ及びその使用
US11077172B2 (en) 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
BR122020025384B1 (pt) 2016-12-13 2022-07-12 Delinia, Inc Proteínas de fusão e dimérica, usos das mesmas e composição farmacêutica
MX2021001493A (es) 2018-08-06 2021-07-15 Medikine Inc Compuestos de fijación al receptor de il-2.
KR20220110207A (ko) 2019-11-05 2022-08-05 메디카인 인코포레이티드 IL-2RβγC 결합 화합물
MX2022005404A (es) * 2019-11-05 2022-09-09 Medikine Inc Compuestos de fijación a il-2r e il-7r dual.
JP2023512687A (ja) 2020-02-03 2023-03-28 メディカイン、インコーポレイテッド ＩＬ－７Ｒα結合化合物
IL295304A (en) 2020-02-03 2022-10-01 Medikine Inc Il-7 receptor alpha gamma c binding compounds, compositions comprising same and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017528444A (ja) 2014-08-11 2017-09-28 デリニア， インコーポレイテッド 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体
WO2017136818A2 (en) 2016-02-05 2017-08-10 Washington University Compositions and methods for targeted cytokine delivery

Also Published As

Publication number Publication date
IL292803A (en) 2022-07-01
EP4055036A4 (en) 2024-02-28
BR112022008750A2 (pt) 2022-07-19
MX2022005404A (es) 2022-09-09
JP2024056696A (ja) 2024-04-23
AU2020378282B2 (en) 2023-05-18
JP2022553826A (ja) 2022-12-26
US11248030B2 (en) 2022-02-15
AU2023214299A1 (en) 2023-10-26
US20220119465A1 (en) 2022-04-21
TW202132330A (zh) 2021-09-01
EP4055036A1 (en) 2022-09-14
WO2021092081A1 (en) 2021-05-14
KR20220110209A (ko) 2022-08-05
US20210130424A1 (en) 2021-05-06
CA3160466A1 (en) 2021-05-14
AU2020378282A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
JP7427287B2 (ja) 二重ｉｌ－２ｒおよびｉｌ－７ｒ結合化合物
JP7427286B2 (ja) ＩＬ－２ＲβγＣ結合化合物
US11965015B2 (en) IL-7R-α-γ binding compounds
JP2023548861A (ja) ＩＬ－２Ｒβγｃ結合化合物及びその使用
US20220119492A1 (en) Il-2r-beta-gamma binding compounds and uses thereof
CN116829579A (zh) Il-2r和il-7r双重结合化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240117

R150 Certificate of patent or registration of utility model

Ref document number: 7427287

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150